Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

Eli Lilly’s weight loss drug Zepbound led to significantly greater weight loss than Novo Nordisk’s Wegovy in a 72-week, head-to-head clinical trial, according to findings published in The New England ...

Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average ... who led the study and presented the findings Sunday at the European Congress on Obesity in Spain.

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average ... who led the study and presented the findings Sunday at the European Congress on Obesity in Spain.